Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Appendix 3Z - Lucy Turnbull (ASX:IMM)

To view the appendix, download the attached PDF.

Immutep - Appendix 3X - Lis Boyce (ASX:IMM)

To view the appendix, download the attached PDF.

Immutep Announces Changes to the Board (ASX:IMM)

SYDNEY, AUSTRALIA – 11 April 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing n...read more

Immutep - Positive Final Data in 2nd Line Metastatic NSCLC Patients (ASX:IMM)

-- Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care chemotherapy -- 83...read more

Immutep - Change in substantial holding (ASX:IMM)

To view the notification, download the attached PDF.

Immutep - Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC (ASX:IMM)

Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients Expansion based on safety and strong initial effica...read more

Immutep - Abstract accepted for ESMO's European Lung Cancer Congress (ASX:IMM)

2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 thera...read more

Immutep - Initiation of Ph 2/3 Trial for Metastatic Breast Cancer (ASX:IMM)

Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA and MAA HR+/HER2-neg/low metastatic breast cancer (MBC) patient ...read more

Immutep - Half Yearly Report and Accounts (ASX:IMM)

To view the report, download the attached PDF.

Immutep - Enrolment Target Reached for INSIGHT-003 Trial in NSCLC (ASX:IMM)

20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

-- Second US FDA Fast Track designation granted to eftilagimod alpha (efti) supporting planned late-stage development in 1st line non-small cell lung cancer (1L NSCLC) -- Compelling Phase II result...read more

Notification of cessation of securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Immutep - TACTI-003 trial 50% enrolment milestone has been achieved (ASX:IMM)

SYDNEY, AUSTRALIA – 4 January 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...read more

Immutep - Update on MBC trial design following successful FDA meeting (ASX:IMM)

-- Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patients -- Patient p...read more

Immutep - Change of Director's Interest Notice L Turnbull (ASX:IMM)

To view the notice, download the attached PDF.

Viewing: 106 - 120 of 200 Previous | Next